vTv Therapeutics Reports Q3 Net Loss of $11.6 Million; CATT1 Enrollment Complete
vTv Therapeutics reported a third-quarter 2026 net loss attributable to shareholders of $11.6 million, or $0.94 per share, versus a loss of $8.7 million, or $1.08 per share, a year earlier. It had $77.2 million in cash and cash equivalents at September 30, 2026.
vTv Therapeutics reported a third-quarter 2026 net loss attributable to shareholders of $11.6 million, or $0.94 per share, compared with a loss of $8.7 million, or $1.08 per share, a year earlier. The company had $77.2 million in cash and cash equivalents at September 30, 2026, and said it expects…